
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01+RDFa 1.0//EN"
"http://www.w3.org/MarkUp/DTD/html401-rdfa-1.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/">
<head>
<title>The Use of Gabexate Mesylate and Ulinastatin for the Prevention of Post-Endoscopic Retrograde... - UKPMC Article - Europe PubMed Central</title>
<link rel="SHORTCUT ICON" href="../images/favicon.ico" type="image/x-icon"/>
<link rel="alternate" type="application/rss+xml"
title="Europe PMC: Popular articles"
href="http://europepmc.org/Funders/RSS/MostViewedArticles.xml">
<link rel="alternate" type="application/rss+xml"
title="Europe PMC: Recent articles"
href="http://europepmc.org/Funders/RSS/AllFunders.xml">
<link rel="alternate" type="application/rss+xml"
title="Europe PMC: Latest journals"
href="http://europepmc.org/Funders/rss/NewJournals.xml">
<link rel="alternate" type="application/rss+xml"
title="Europe PMC: Content Holdings"
href="http://europepmc.org/contentrss">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
<meta name="author" content="Europe PubMed Central (Europe PMC)"/>
<meta name="owner" content="Europe PubMed Central (Europe PMC)"/>
<meta name="keywords" content="Europe PMC, Europe PubMed Central, UK PhD Theses/Thesis, UK Clinical Guidelines, UK Research Reports, Biological Patents, life sciences, bioinformatics, biomedical research, health research, journal articles, citation search, medical journals"/>
<meta name="description" content="Europe PubMed Central (Europe PMC) is an archive of life sciences journal literature."/>

<link rel="search" type="application/opensearchdescription+xml" title="Search Europe PMC" href="http://europepmc.org/tools/opensearch_epmc.xml">
<link rel="stylesheet" href="../template/jquery_ui.css" type="text/css" media="print, projection, screen"/>
<link rel="stylesheet" href="../template/jquery_menu.css" type="text/css" media="screen, projection"/>
<!--[if lte IE 7]>
<link rel="stylesheet" type="text/css" href="/template/jquery_menu_ie.css" media="screen" />
<![endif]-->

<script src="../template/yahoo-min.js" type="text/javascript"></script>
<script src="../template/dom-min.js" type="text/javascript"></script>
<script src="../template/enrichment.js" type="text/javascript"></script>
<link rel="stylesheet" href="../template/enrichment.css" type="text/css" media="print, projection, screen"/>


<script type="text/javascript" src="../Scripts/jquery-1.4.2.min.js"></script>
<script type="text/javascript" language="javascript" src="../template/hoverIntent.js"></script>
<script type="text/javascript" language="javascript" src="../template/jquery.js"></script>
<script src="../template/jquery_ui_002.js" type="text/javascript"></script>
<script src="../template/jquery_ui_min.js" type="text/javascript"></script>
<script src="../urchin.js" type="text/javascript"></script>
<script type="text/javascript">
urchinTracker();
</script>
<script src="../template/epmc.js" type="text/javascript"></script>
<link href="../template/epmc.css" rel="stylesheet" type="text/css"/>
<script type="text/javascript">ie7 = false;</script>
<!--[if IE 7]>
<link href="/template/ie7.css" rel="stylesheet" type="text/css"/>
<script type="text/javascript">ie7 = true;</script>
<![endif]-->
<!--[if IE 8]>
<link href="/template/ie8.css" rel="stylesheet" type="text/css"/>
<![endif]-->
<!--[if IE 9]>
<link href="/template/ie9.css" rel="stylesheet" type="text/css"/>
<meta http-equiv="X-UA-Compatible" content="IE=9"/>
<![endif]-->
<!--[if lt IE 9]>
<script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
<![endif]-->
<!--
<script src="/Scripts/jquery-ui-1.7.2.custom.min.js" type="text/javascript"></script>
-->

<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="http://europepmc.org/articles/PMC3343166/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Gut and Liver" /><meta name="citation_title" content="The Use of Gabexate Mesylate and Ulinastatin for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis" /><meta name="citation_authors" content="Young Wook Yoo, Sang-Woo Cha, Anna Kim, Seung Yeon Na, Young Woo Lee, Sae Hee Kim, Hyang Ie Lee, Yun Jung Lee, Hyeon Woong Yang, Sung Hee Jung" /><meta name="citation_date" content="April 2012" /><meta name="citation_issue" content="2" /><meta name="citation_volume" content="6" /><meta name="citation_firstpage" content="256" /><meta name="citation_doi" content="10.5009/gnl.2012.6.2.256" /><meta name="citation_abstract_html_url" content="http://europepmc.org/articles/PMC3343166/?report=abstract" /><meta name="citation_pmid" content="22570757" /><meta name="DC.Title" content="The Use of Gabexate Mesylate and Ulinastatin for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Editorial Office of Gut and Liver" /><meta name="DC.Contributor" content="Young Wook Yoo" /><meta name="DC.Contributor" content="Sang-Woo Cha" /><meta name="DC.Contributor" content="Anna Kim" /><meta name="DC.Contributor" content="Seung Yeon Na" /><meta name="DC.Contributor" content="Young Woo Lee" /><meta name="DC.Contributor" content="Sae Hee Kim" /><meta name="DC.Contributor" content="Hyang Ie Lee" /><meta name="DC.Contributor" content="Yun Jung Lee" /><meta name="DC.Contributor" content="Hyeon Woong Yang" /><meta name="DC.Contributor" content="Sung Hee Jung" /><meta name="DC.Date" content="2012 April" /><meta name="DC.Identifier" content="10.5009/gnl.2012.6.2.256" /><meta name="DC.Language" content="en" /><link rel="stylesheet" href="../corehtml/pmc/css/pmcstatic.css" type="text/css" /><link rel="stylesheet" href="../corehtml/pmc/css/pmcbase1.css" type="text/css" /><link rel="stylesheet" href="../corehtml/pmc/css/pmcbars-slateblue.css" type="text/css" /><link rel="stylesheet" href="../corehtml/pmc/css/pmcbody4.css" type="text/css" /><link rel="stylesheet" href="../corehtml/pmc/css/pmcrefs1.css" type="text/css" /><link rel="stylesheet" href="../corehtml/pmc/css/pmcbase1-prnt.css" type="text/css" media="print" /><link rel="stylesheet" href="../corehtml/pmc/css/pmcbase1-scrn.css" type="text/css" media="screen" /><style type="text/css">.print-view{display:block}</style><script type="text/javascript" src="../corehtml/pmc/js/jquery-1.4.4.min.js"></script><script type="text/javascript" src="../corehtml/pmc/js/jquery.hoverIntent.min.js"></script><script type="text/javascript" src="../corehtml/pmc/js/NcbiTagServer.min.js"></script><script type="text/javascript" src="../corehtml/pmc/js/common.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="../corehtml/pmc/js/noext.menu.js"></script><link type="text/css" rel="stylesheet" href="../corehtml/pmc/css/noext-menu.css" /><link rel="stylesheet" href="../corehtml/pmc/css/ptpmc.css" type="text/css" /><style type="text/css">.pmc-watermark {background:transparent url(../corehtml/pmc/pmcgifs/wm-gutliver.gif)  repeat-y top left;}.print-view{display:block}</style>


<script type="text/javascript">
$(function()
{
$("#Highlight_head").click(function(event) {
event.preventDefault();
$("#Highlight_body").slideToggle();
});
$("#Highlight_body a").click(function(event) {
event.preventDefault();
$("#Highlight_body").slideUp();
});
});
</script>
<script type="text/javascript" language="javascript" src="../template/hoverIntent.js"></script>
<script type="text/javascript" language="javascript" src="../template/jquery.js"></script>
<script src="../template/jquery_ui_002.js" type="text/javascript"></script>
<script src="../template/jquery_ui.js" type="text/javascript"></script>
<script type="text/javascript" src="../resources/org.apache.wicket.markup.html.WicketEventReference/wicket-event.js"></script>
<script type="text/javascript" src="../resources/org.apache.wicket.ajax.WicketAjaxReference/wicket-ajax.js"></script>
<script type="text/javascript" src="../resources/org.apache.wicket.extensions.ajax.markup.html.modal.ModalWindow/res/modal.js"></script>
<link rel="stylesheet" type="text/css" href="../resources/org.apache.wicket.extensions.ajax.markup.html.modal.ModalWindow/res/modal.css" />

<link rel="schema.DC" href="http://purl.org/dc/elements/1.1/" />
<link rel="schema.DCTERMS" href="http://purl.org/dc/terms/" />

<meta name="citation_journal_title" content="" datatype="xsd:string"/>

<meta name="citation_date" content="" datatype="xsd:date"/>

<meta name="citation_issn" content="" datatype="xsd:string"/>

<meta name="citation_issue" content="" datatype="xsd:integer"/>

<meta name="citation_volume" content="" datatype="xsd:integer"/>

<meta name="citation_firstpage" content="" datatype="xsd:integer"/>

<meta name="citation_title" content="" datatype="xsd:string"/>

<meta name="citation_pmid" content="" datatype="xsd:string" SCHEME="PMID"/>

<meta name="citation_authors" content="" datatype="xsd:string"/>





<span style="display:none" property="dc:abstract" datatype="xsd:string"> BACKGROUND/AIMS: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Only a few pharmacologic agents have been shown to have potential efficacy for the prophylactic treatment of post-ERCP pancreatitis (PEP). The aim of this study was to determine whether prophylactic gabexate and ulinastatin can decrease the incidence of PEP. METHODS: From January 2005 to April 2010, 1,679 patients undergoing ERCP treatment were consecutively enrolled in the study. After selective exclusion, a total of 1,480 patients were included in the analysis. The patients were separated into 3 groups according to the prophylactic administration of gabexate (593 patients), ulinastatin (229 patients), or saline solution (658 patients) and analyzed retrospectively. The primary outcome measurements were the incidence of pancreatitis and hyperamylasemia. RESULTS: PEP occurred in 21 of the 593 (3.5%) patients who received gabexate, 16 of the 229 (7.0%) patients who received ulinastatin, and 48 of the 658 (7.3%) patients who received a saline solution. The incidence of PEP was significantly different between the gabexate and ulinastatin or saline solution groups (p&lt;0.05). CONCLUSIONS: Gabexate prophylaxis is effective in preventing PEP. However, there is no difference in the beneficial effects of the prophylactic administration of ulinastatin and a saline solution.</span>


<meta name="DC.Date" content="" datatype="xsd:date" property="dc:date"/>

<meta name="DCTERMS.isPartOf" content="" datatype="xsd:string" property="dcterms:isPartOf"/>

<meta name="DC.Identifier" content="" datatype="xsd:string" SCHEME="PMID" property="dc:identifier"/>

<meta name="DC.Title" content="" datatype="xsd:string" property="dc:title"/>

<meta name="DC.Type" content="" datatype="xsd:string" property="dc:type"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Creator" content="" datatype="xsd:string" property="dc:creator"/>

<meta name="DC.Contributor" content="" datatype="xsd:string" property="dc:contributor"/>

<meta name="DC.Language" content="" datatype="xsd:string" property="dc:language"/>

<script type="text/javascript" ><!--/*--><![CDATA[/*><!--*/
Wicket.Event.add(window, "domready", function(event) { var wcall=wicketAjaxGet('../?wicket:interface=:4:relatedcitation::IBehaviorListener:0:1',function() { }.bind(this),function() { }.bind(this), function() {return Wicket.$('id25') != null;}.bind(this));;});
/*-->]]>*/</script>

<script type="text/javascript" ><!--/*--><![CDATA[/*><!--*/
Wicket.Event.add(window, "domready", function(event) { var wcall=wicketAjaxGet('../?wicket:interface=:4:relatedArts::IBehaviorListener:0:1',function() { }.bind(this),function() { }.bind(this), function() {return Wicket.$('id26') != null;}.bind(this));;});
/*-->]]>*/</script>


<script type="text/javascript" ><!--/*--><![CDATA[/*><!--*/
Wicket.Event.add(window, "domready", function(event) { var wcall=wicketAjaxGet('../?wicket:interface=:4:relatedpubmedArts::IBehaviorListener:0:1',function() { }.bind(this),function() { }.bind(this), function() {return Wicket.$('id27') != null;}.bind(this));;});
/*-->]]>*/</script>



<meta name="DCTERMS.hasFormat" content="" datatype="xsd:anyURI" SCHEME="fulltext" property="dcterms:hasFormat" type="text/html"/>

<meta name="citation_fulltext_html_url" content="" datatype="xsd:anyURI" SCHEME="FullText"/>

<meta name="DC.Identifier" content="" datatype="xsd:string" SCHEME="PMCID" property="dc:identifier"/>

<meta name="DCTERMS.hasFormat" content="" datatype="xsd:anyURI" SCHEME="abstract" property="dcterms:hasFormat" type="text/html"/>

<meta name="citation_abstract_html_url" content="" datatype="xsd:anyURI" SCHEME="Abstract"/>

<meta name="DCTERMS.hasFormat" content="" datatype="xsd:anyURI" SCHEME="pdf" property="dcterms:hasFormat" type="application/pdf"/>

<meta name="citation_pdf_url" content="" datatype="xsd:anyURI" SCHEME="PDF"/>

</head>
<body align="center" height="100%">
<noscript>
<div align="center">
<p>
<b>Europe PubMed Central (Europe PMC)</b> requires Javascript to function effectively.
</p>
<p>
Either your web browser doesn't support Javascript or it is currently turned off.
In the latter case, please turn on Javascript support in your web browser and reload this page.
</p>
</div>
</noscript>
<div class="page_proper">
<header>
<div id="epmc_pageHeader">
<div>


<a href="http://europepmc.org/feedback/?wicket:pageMapName=ukpmc_feedback&amp;url=/ukpmc/articles/PMC3343166" class="ukpmc_toolbar feedbackLink" onmouseover="Tip('Leave your feedback')" onmouseout="UnTip()" onclick="var w = window.open(href, 'ukpmc_feedback', 'scrollbars=no,location=no,menuBar=no,resizable=no,status=no,toolbar=no,width=550,height=650'); if(w.blur) w.focus(); return false;" target="ukpmc_feedback"><img alt="Leave your feedback" src="../images/feedback_icon.gif" border="0"/>Feedback</a>


<nav>
<ul class="dropdown" id="epmc_mainNav">
<li class="about first">
<a href="http://europepmc.org/About" ACCESSKEY="A">About</a>
<ul class="sub_menu">
<li>
<a href="http://europepmc.org/Funders">
<span>Funders</span>

</a>
</li><li>
<a href="http://europepmc.org/Governance">
<span>Governance</span>

</a>
</li><li>
<a href="http://europepmc.org/ContactUs">
<span>Contact us</span>

</a>
</li>
</ul>
</li>
<li>
<a href="http://europepmc.org/RssFeeds" ACCESSKEY="N">RSS Feeds</a>
</li>
<li>
<a href="http://europepmc.org/journalList" ACCESSKEY="J">Journal List</a>
</li>
<li>
<a href="http://europepmc.org/GrantLookup/" ACCESSKEY="G">Grant Lookup</a>
</li>
<li class="help">
<a href="http://europepmc.org/FAQ" ACCESSKEY="F">FAQ and Guides</a>
<ul class="sub_menu">
<li>
<a href="http://europepmc.org/Guides">Guides</a>
</li>
</ul>
</li>
<li class="plus">
<a href="http://plus.europepmc.org" target="epmcplus" onmouseover="Tip('Submit your manuscripts, manage your grants and publish your research impact using &lt;b&gt;Europe PMC plus&lt;/b&gt;')" onmouseout="UnTip()">
<span>Europe PMC plus</span>
</a>
</li>
<li class="labs last">
<a href="http://labs.europepmc.org/" onmouseover="Tip('Prototypes of semantic applications')" onmouseout="UnTip()">
<span>Europe PMC labs</span>
</a>
</li>
</ul>
</nav>
</div>
</div>
</header>
<div id="epmc_pageBody">



<div>
<div id="epmc_searchBanner">
<div class="holder">
<div class="logo">
<a href="http://europepmc.org/" target="_top" ACCESSKEY="U">
<h1>Europe PubMed Central</h1>
</a>
</div>
<div class="search">
<form action="http://europepmc.org/articles/?wicket:interface=:4:search:searchForm::IFormSubmitListener::" method="post" id="id28" name="searchForm11" accept-charset="UTF-8"><div style="display:none"><input type="hidden" name="id28_hf_0" id="id28_hf_0" /></div>
<input type="text" id="textfield" name="searchString" maxlength="300" size="50" placeholder="search for..." value=""/>
<input value="Search" type="submit" />
</form>
<a href="http://europepmc.org/advancesearch" class="advancedSearch" title="Advanced Search">Advanced Search</a>
<div class="epmc_searchTools">

<a href="http://europepmc.org/?wicket:interface=:4:search:recentsearches::ILinkListener::" class="ukpmc_toolbar" onmouseover="Tip('View your Recent Activity summary.', DELAY, 1000)" onmouseout="UnTip()" id="id29" onclick="var wcall=wicketAjaxGet('../?wicket:interface=:4:search:recentsearches::IBehaviorListener:0:1',function() { }.bind(this),function() { }.bind(this), function() {return Wicket.$('id29') != null;}.bind(this));return !wcall;">
<img alt="View summary of your Recent Activity" src="../images/recentactivityICON_small.png" border="0"/>
Recent Activity
</a>
<div id="id2a" style="display:none">
<div id="id2b" style="display:none"></div>
</div>
&#160;|&#160;
<a href="http://europepmc.org/?wicket:interface=:4:search:clipboard::ILinkListener::" class="ukpmc_toolbar" onmouseover="Tip('View your Clipboard summary.<br/>The Clipboard is a temporary store for items of interest to you.<br/>The items in your Clipboard may be cleared after 24 hours.', DELAY, 1000)" onmouseout="UnTip()" id="id2c" onclick="var wcall=wicketAjaxGet('../?wicket:interface=:4:search:clipboard::IBehaviorListener:0:1',function() { }.bind(this),function() { }.bind(this), function() {return Wicket.$('id2c') != null;}.bind(this));return !wcall;">
<img alt="View summary of your Clipboard" src="../images/clipboardICON_small.png" border="0"/>
Clipboard
</a>
<div id="id2d" style="display:none">
<div id="id2e" style="display:none"></div>
</div>

</div>
</div>
</div>
</div>
<div>

</div>
</div>
<div class="epmc_pageHolder articleContentPage">
<div class="epmc_wideLeft">
<div id="container-1">

<div class="epmc_citationName">
<div class="clipboard_icon">
<span>
<a href="http://europepmc.org/?wicket:interface=:4:clipboard_icon:addclipboard::ILinkListener::" id="id2f" onclick="var wcall=wicketAjaxGet('../?wicket:interface=:4:clipboard_icon:addclipboard::IBehaviorListener:0:1',function() { }.bind(this),function() { }.bind(this), function() {return Wicket.$('id2f') != null;}.bind(this));return !wcall;">
<img style="vertical-align:top;" border="0" onmouseover="Tip('Add Citation to Clipboard')" onmouseout="UnTip()" onclick="toggle(this)" id="id30" src="../resources/uk.bl.ukpmc.web.pages.main.Home/images/small_clipboard_off.gif"/></a>
</span>
</div>
<div class="title">
<span class="abs_citation_title"><span>The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.</span></span>
</div>
<div class="abs_nonlink_metadata">(PMCID:PMC3343166)</div>
</div>

<ul class="ui-tabs-nav">
<li class="ui-tabs-selected" id="fulltext">
<a href="PMC3343166.html#fragment-fulltext">
<span>Full Text

<img src="../resources/uk.bl.ukpmc.web.panels.images.UkpmcFavicon/small_logo.gif" border="0" alt="This article is available in Europe PMC" height="14" width="14" onmouseover="Tip('The full text of this article is available in Europe PMC', DELAY, 1000)" onmouseout="UnTip()"/>

</span>
</a>
</li>
<li id="relatedCitations" class="ui-tabs-disabled"><a href="PMC3343166.html#fragment-related-citations" id="relatedcitation_link"><span>Citations <img alt="List of citations in Europe PMC which this record is cited by and<br/> those which it cites" border="0" src="../images/qmark.png" onmouseover="Tip('List of citations in Europe PMC which this record is cited by and<br/> those which it cites')" onmouseout="UnTip()"/></span></a></li>
<li id="relatedarts" class="ui-tabs-disabled"><a href="PMC3343166.html#fragment-related-bioentities" id="relatedentity_link"><span>BioEntities <img alt="Biological entities annotated by the EMBL EBI and NCBI teams" border="0" src="../images/qmark.png" onmouseover="Tip('Biological entities annotated by the EMBL EBI and NCBI teams')" onmouseout="UnTip()"/></span></a></li>
<li id="relatedpubmedarts" class="ui-tabs-disabled"><a href="PMC3343166.html#fragment-related-pubmedarts" id="relatedarts_link"><span>Related Articles <img alt="Articles closely related to the current article derived by NCBI <br/>by comparing subject headings and words in the title and abstract" border="0" src="../images/qmark.png" onmouseover="Tip('Articles closely related to the current article derived by NCBI <br/>by comparing subject headings and words in the title and abstract')" onmouseout="UnTip()"/></span></a></li>
</ul>
<div class="ui-tabs-panel" id="fragment-fulltext">
<table width="100%">
<tr>
<td align="left" class="pmc-watermark"></td>
<td valign="top">
<div align="left">
<small>
<div><img align="top" style="border-style: none" src="../corehtml/pmc/pmcgifs/logo-gutliver-art.gif" alt="Logo of gutliver" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="44,56,105,75" alt="This Article" title="This Article" href="http://dx.crossref.org/10.5009/gnl.2012.6.2.256" ref="reftype=publisher&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText&amp;rendering-type=normal" target="pmc_ext" onclick="focuswin('pmc_ext')" /><area shape="rect" coords="124,56,218,75" alt="Aims and Scope" title="Aims and Scope" href="http://gutnliver.org/about.html" ref="reftype=publisher&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" onclick="focuswin('pmc_ext')" /><area shape="rect" coords="237,56,362,75" alt="Instructions to Authors" title="Instructions to Authors" href="http://gutnliver.org/check.html" ref="reftype=publisher&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" onclick="focuswin('pmc_ext')" /><area shape="rect" coords="380,56,459,75" alt="E-Submission" title="E-Submission" href="http://www.gutnliver.org/thesis/" ref="reftype=publisher&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" onclick="focuswin('pmc_ext')" /><area shape="rect" coords="0,0,500,55" alt="Gut and Liver" title="Gut and Liver" href="http://gutnliver.org/" ref="reftype=publisher&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext" onclick="focuswin('pmc_ext')" /></map></div> 
</small>
</div>
<div class="front-matter-section"><table cellspacing="0" cellpadding="0" width="100%"><tr style="vertical-align: top"><td><div class="fm-citation"><div><div><span class="citation-version"></span><span class="citation-abbreviation">Gut Liver. </span><span class="citation-publication-date">2012 April; </span><span class="citation-volume">6</span><span class="citation-issue">(2)</span><span class="citation-flpages">: 256–261. </span></div><div><span class="fm-vol-iss-date">Published online 2012 April 17. </span><span class="fm-vol-iss-date"> </span><span class="fm-vol-iss-date">doi:  <a class="ref-extlink" href="http://dx.crossref.org/10.5009%2Fgnl.2012.6.2.256" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=other&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.5009/gnl.2012.6.2.256</a></span></div></div></div></td><td class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3343166</span></div></td></tr></table><div class="fm-copyright"><a class="int-reflink" href="http://europepmc.org/articles/ppmc-localhtml/copyright.html">Copyright</a>  &#x000a9; 2012 by the Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer</div><div class="fm-title">The Use of Gabexate Mesylate and Ulinastatin for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis</div><div class="contrib-group fm-author">Young Wook Yoo,<sup>*</sup> Sang-Woo Cha,<sup><img src="../corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>&#x02020;</sup> Anna Kim,<sup>&#x02021;</sup> Seung Yeon Na,<sup>&#x02021;</sup> Young Woo Lee,<sup>&#x02021;</sup> Sae Hee Kim,<sup>&#x02021;</sup> Hyang Ie Lee,<sup>&#x02021;</sup> Yun Jung Lee,<sup>&#x02021;</sup> Hyeon Woong Yang,<sup>&#x02021;</sup> and  Sung Hee Jung<sup>&#x02021;</sup></div><div class="fm-affl"><sup>*</sup>Gastroenterology and Hepatobiliary Center, Department of Internal Medicine, Cheongju St. Mary's Hospital, Cheongju, Korea.</div><div class="fm-affl"><sup>&#x02020;</sup>Institute for Digestive Research, Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.</div><div class="fm-affl"><sup>&#x02021;</sup>Division of Gastroenterology, Department of Internal Medicine, Daejeon Eulji University Hospital, Eulji University College of Medicine, Daejeon, Korea.</div><div class="fm-footnote"><sup><img src="../corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div class="fm-footnote" id="__correspid270051"> Correspondence to: Sang-Woo Cha. Institute for Digestive Research, Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University School of Medicine, 59 Daesagwan-ro, Yongsan-gu, Seoul 140-743, Korea. Tel: +82-2-709-9212, Fax: +82-2-709-9696, <span class="before-email-separator"></span><span class="email-label">Email: </span><span class="e_id270053">swcha/at/schmc.ac.kr</span><script type="text/javascript" language="JavaScript"><!--
                                    try{initUnObscureEmail ("e_id270053", '<a class="ext-reflink" href="' + reverseAndReplaceString('rk.ca.cmhcs/ta/ahcws:otliam', '/at/', '@') + '">' + reverseAndReplaceString('rk.ca.cmhcs/ta/ahcws', '/at/','@') + '</a>')}catch(e){}
                                //--></script></div><div class="fm-pubdate">Received January 7, 2011; Revised July 28, 2011; Accepted September 16, 2011.</div><div class="fm-copyright"><div class="p p-first-last" id="__license-pid270114">This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<a href="http://creativecommons.org/licenses/by-nc/3.0" class="ext-reflink " ref="reftype=extlink&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext" onclick="focuswin('pmc_ext')">http://creativecommons.org/licenses/by-nc/3.0</a>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></div></div><div id="__abstractid270123" class="sec"><div class="head1 section-title" id="__abstractid270123titletitle" style="text-transform: none;"><div class="other-sections"><ul class="noext-menu noext-menu-hidden"><li><a class="first-link" href="PMC3343166.html#"> Other Sections▼</a><ul class="submenu head1"><li class="submenu-item current-item"><a class="" href="PMC3343166.html#" onclick="return(false)" style="text-transform: none;">Abstract</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270156" class="" style="text-transform: none;">INTRODUCTION</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270197" class="" style="text-transform: none;">MATERIALS AND METHODS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270248" class="" style="text-transform: none;">RESULTS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270297" class="" style="text-transform: none;">DISCUSSION</a></li><li class="submenu-item"><a href="PMC3343166.html#__ref-listid270428" class="" style="text-transform: none;">References</a></li></ul></li></ul></div><div>Abstract</div></div><div class="section-content" id="__abstractid270123content"><!--article-meta--><div id="__secid270124" class="sec sec-first"><div class="abs-head2 head-separate">Background/Aims</div><div class="p p-first-last" id="__pid270127">Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Only a few pharmacologic agents have been shown to have potential efficacy for the prophylactic treatment of post-ERCP pancreatitis (PEP). The aim of this study was to determine whether prophylactic gabexate and ulinastatin can decrease the incidence of PEP.</div></div><div id="__secid270129" class="sec"><div class="abs-head2 head-separate">Methods</div><div class="p p-first-last" id="__pid270132">From January 2005 to April 2010, 1,679 patients undergoing ERCP treatment were consecutively enrolled in the study. After selective exclusion, a total of 1,480 patients were included in the analysis. The patients were separated into 3 groups according to the prophylactic administration of gabexate (593 patients), ulinastatin (229 patients), or saline solution (658 patients) and analyzed retrospectively. The primary outcome measurements were the incidence of pancreatitis and hyperamylasemia.</div></div><div id="__secid270134" class="sec"><div class="abs-head2 head-separate">Results</div><div class="p p-first-last" id="__pid270138">PEP occurred in 21 of the 593 (3.5%) patients who received gabexate, 16 of the 229 (7.0%) patients who received ulinastatin, and 48 of the 658 (7.3%) patients who received a saline solution. The incidence of PEP was significantly different between the gabexate and ulinastatin or saline solution groups (p&#x0003c;0.05).</div></div><div id="__secid270140" class="sec sec-last"><div class="abs-head2 head-separate">Conclusions</div><div class="p p-first-last" id="__pid270143">Gabexate prophylaxis is effective in preventing PEP. However, there is no difference in the beneficial effects of the prophylactic administration of ulinastatin and a saline solution.</div></div><div class="p"><span class="kwd-label">Keywords: </span><span class="kwd-text">Endoscopic retrograde cholangiopancreatography, Pancreatitis, Gabexate, Ulinastatin</span></div></div></div><div id="__secid270156" class="sec"><div class="head1 section-title" id="__secid270156titletitle" style="text-transform: none;"><div class="other-sections"><ul class="noext-menu noext-menu-hidden"><li><a class="first-link" href="PMC3343166.html#"> Other Sections▼</a><ul class="submenu head1"><li class="submenu-item"><a href="PMC3343166.html#__abstractid270123" class="" style="text-transform: none;">Abstract</a></li><li class="submenu-item current-item"><a class="" href="PMC3343166.html#" onclick="return(false)" style="text-transform: none;">INTRODUCTION</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270197" class="" style="text-transform: none;">MATERIALS AND METHODS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270248" class="" style="text-transform: none;">RESULTS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270297" class="" style="text-transform: none;">DISCUSSION</a></li><li class="submenu-item"><a href="PMC3343166.html#__ref-listid270428" class="" style="text-transform: none;">References</a></li></ul></li></ul></div><div>INTRODUCTION</div></div><div class="section-content" id="__secid270156content"><div class="p p-first" id="__pid270159">Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), it is most often clinically mild or moderate in severity but in about 10% of cases it is severe and potentially fatal.<sup><a href="http://europepmc.org/abstract/MED/20506068" rid="B1" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">1</a></sup> Despite improvements in technology and more experience in ERCP, the incidence of post-ERCP pancreatitis (PEP) has not yet decreased significantly. PEP is associated with substantial morbidity and even mortality. Although the pathophysiology of PEP is not completely understood, numerous factors, including hydrostatic injury, obstruction of pancreatic juice outflow, thermal injury from electrocautery current, and chemical or allergic injury, can act independently or in combination to induce PEP.<sup><a href="http://europepmc.org/abstract/MED/8786777" rid="B2" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">2</a></sup></div><div class="p" id="__pid270171">The pharmacologic agents that have been proposed and tested for prophylaxis of PEP are various, but only a few have been shown to have any proven efficacy. In a recent European Society of Gastrointestinal Endoscopy guideline for prophylaxis of PEP<sup><a href="http://europepmc.org/abstract/MED/20506068" rid="B1" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">1</a></sup> non-steroidal anti-inflammatory drugs are the only drugs with proven efficacy. Glyceryl trinitrate (nitroglycerin), ceftazidime, somatostatin, octreotide, and antiprotease drugs are possibly effective drugs. However, glucocorticoids; drugs reducing pressure on the sphincter of Oddi other than nitroglycerin, such as botulinum toxin, epinephrine, lidocaine, and nifedipine; antioxidant drugs such as allopurinol, n-acetylcysteine, and heparin; and interleukin-10 were proven ineffective.<sup><a href="http://europepmc.org/abstract/MED/20506068" rid="B1" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">1</a></sup></div><div class="p" id="__pid270182">Antiproteases, which have been clinically used to manage acute pancreatitis, would theoretically reduce pancreatic injury after ERCP because activation of proteolytic enzymes is considered to play an important role in the pathogenesis of PEP. Currently, three antiproteases; gabexate mesylate, ulinastatin, and nafamostat have been evaluated for their prophylactic efficacy against PEP in prospective randomized controlled trials.<sup><a href="http://europepmc.org/abstract/MED/8786777" rid="B2" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">2</a></sup><sup>-</sup><sup><a href="http://europepmc.org/abstract/MED/19327467" rid="B6" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">6</a></sup> However, most results are controversial, prophylaxis against PEP with these drugs has been carried out using various drug dosages, and no adequate study has been performed to identify the optimal method or dosage of administration of the drugs.</div><div class="p p-last" id="__pid270195">The present study was designed to evaluate retrospectively the efficacy of intravenous gabexate mesylate and ulinastatin in preventing PEP and hyperamylasemia in comparison with control group.</div></div></div><div id="__secid270197" class="sec"><div class="head1 section-title" id="__secid270197titletitle" style="text-transform: none;"><div class="other-sections"><ul class="noext-menu noext-menu-hidden"><li><a class="first-link" href="PMC3343166.html#"> Other Sections▼</a><ul class="submenu head1"><li class="submenu-item"><a href="PMC3343166.html#__abstractid270123" class="" style="text-transform: none;">Abstract</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270156" class="" style="text-transform: none;">INTRODUCTION</a></li><li class="submenu-item current-item"><a class="" href="PMC3343166.html#" onclick="return(false)" style="text-transform: none;">MATERIALS AND METHODS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270248" class="" style="text-transform: none;">RESULTS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270297" class="" style="text-transform: none;">DISCUSSION</a></li><li class="submenu-item"><a href="PMC3343166.html#__ref-listid270428" class="" style="text-transform: none;">References</a></li></ul></li></ul></div><div>MATERIALS AND METHODS</div></div><div class="section-content" id="__secid270197content"><div id="__secid270202" class="sec sec-first"><div class="head2 head-separate">1. Patients</div><div class="p p-first-last" id="__pid270205">From January 2005 to April 2010, 1,679 patients underwent ERCP in the gastrointestinal endoscopy unit of Eulji University Hospital (a tertiary referral center) were consecutively enrolled. Exclusion criteria were as follows: age &#x0003c;19 years, previous sphincterotomy, acute pancreatitis before ERCP, and pregnancy. After selective exclusion, a total of 1,480 patients were included in the analysis. Patients were separated into 3 groups according to the prophylactic administration of a continuous intravenous infusion of gabexate mesylate (400 mg, 593 patients, group A), ulinastatin (150,000 units, 229 patients, group B), or saline solution (658 patients, group C), and analyzed retrospectively (<a href="http://europepmc.org/articles/PMC3343166/figure/F1/" style="text-decoration:none;" onclick="return startTarget(this, 'figure', 1024, 800)" class="fig-table-link fig figpopup" rid-figpopup="F1"><span style="text-decoration: underline;">Fig. 1</span></a>). Written informed consent was obtained from all patients. This study was approved by the Institutional Review Board of our hospital.</div><div class="canvas-figure-ref-outer"><div class="canvas-figure-ref-inner"><table class="thumb-caption" border="0" cellpadding="0" cellspacing="0" style="clear:both; width: 100%;"><tr valign="top" align="left"><td class="thumb-cell"><div class="thumb-ph" id="F1"><a href="http://europepmc.org/articles/PMC3343166/figure/F1/" class="icon-reflink figpopup" target="figure" onclick="return startTarget(this, 'figure', 1024, 800)"><div class="small-thumb-canvas"><div class="small-thumb-canvas-1"><img src="PMC3343166/bin/gnl-6-256-g001.gif" class="icon-reflink small-thumb" alt="Fig. 1" title="Fig. 1" src-large="http://europepmc.org/articles/PMC3343166/bin/gnl-6-256-g001.jpg" /></div></div></a></div></td><td class="caption-cell"><div class="caption-ph"><a class="side-caption" href="http://europepmc.org/articles/PMC3343166/figure/F1/" onclick="return startTarget(this, 'figure', 1024, 800)"><strong>Fig. 1</strong></a><div class="figure-table-caption-in-article"><span>Study flow diagram.</span></div><div class="figure-table-caption-in-article"></div></div></td></tr></table><div class="figure-table-caption-in-article"></div></div></div></div><div id="__secid270212" class="sec"><div class="head2 head-separate">2. Administration of gabexate mesylate or ulinastatin, and follow-up</div><div class="p p-first-last" id="__pid270216">Four hundred milligram of gabexate mesylate (Foy; Dong-A Pharmaceutical, Seoul, Korea) or 150,000 units of ulinastatin (Ulistin; Hanlim Pharmacy, Seoul, Korea) was dissolved in 500 mL of 5% dextrose solution and administered by continuous intravenous infusion beginning 30 minutes before ERCP and continuing for 24 hours afterwards. In group C, 500 mL of saline solution was administered by continuous infusion during the same time as control (<a href="http://europepmc.org/articles/PMC3343166/figure/F1/" style="text-decoration:none;" onclick="return startTarget(this, 'figure', 1024, 800)" class="fig-table-link fig figpopup" rid-figpopup="F1"><span style="text-decoration: underline;">Fig. 1</span></a>). Benzodiazepines, anti-spasmodic agents, and non-narcotic analgesics, alone or in combination, were administered routinely before the procedure. Therapy with antibiotics and analgesics was allowed to be continued. Two senior endoscopists directly performed all the procedures using side-viewing endoscopes (JF-240, JF-260V, and TJF-240; Olympus Optical Co., Ltd., Tokyo, Japan). Serum amylase and lipase levels were checked before ERCP, 4 and 24 hours after ERCP, and when clinically indicated. The presence of abdominal pain attributable to the pancreas and the use and type of analgesic therapy at those times were evaluated. The primary outcome measurements were the incidence of pancreatitis and hyperamylasemia.</div></div><div id="__secid270223" class="sec"><div class="head2 head-separate">3. Definitions</div><div class="p p-first-last" id="__pid270226">The definition of PEP was based on the consensus criteria.<sup><a href="http://europepmc.org/abstract/MED/2070995" rid="B7" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">7</a></sup> It was defined as the following: a newly developed or increased abdominal pain within 24 hours after ERCP requiring analgesic agents, and the elevation of serum amylase and/or lipase level at least 3 times the normal upper limit about 24 hours after the procedure. The severity was graded mild when hospitalization lasted 2 to 3 days, moderate when it lasted 4 to 10 days, and severe when it was prolonged for more than 10 days or any of the following complications occurred: hemorrhagic pancreatitis, pancreatic necrosis, pancreatic pseudocyst, or a need for percutaneous drainage or surgery. Hyperamylasemia was defined as elevation of serum amylase levels to more than 3 times the normal upper limit at 4 and/or 24 hours after the ERCP without other symptoms. Visualization of the entire pancreatic duct by contrast injection was regarded as pancreatic injection. Precut sphincterotomy was performed at the periampullary area, and infundibulotomy was not performed. Difficult cannulation, based on the number of attempts on the papilla with a cannulating instrument, was defined as more than 10 attempts occurred, or failure of cannulation after 10 minutes.<sup><a href="http://europepmc.org/abstract/MED/17531632" rid="B8" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">8</a></sup> Failed selective bile duct cannulation was categorized into the "difficult cannulation" group.</div></div><div id="__secid270239" class="sec sec-last"><div class="head2 head-separate">4. Statistical analysis</div><div class="p p-first-last" id="__pid270242">The &#x003c7;<sup>2</sup> and Fisher exact test were used for comparisons of categorical data. All continuous data values were expressed as means&#x000b1;SD. Differences in variance of the data between the 3 groups were examined by repeated measures analysis of variance and Bonferroni's method was employed for within subjects comparisons. Differences in the mean values were examined by Student's t-test. A p&#x0003c;0.05 indicated statistical significance. Statistical calculations were performed with SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, USA).</div></div></div></div><div id="__secid270248" class="sec"><div class="head1 section-title" id="__secid270248titletitle" style="text-transform: none;"><div class="other-sections"><ul class="noext-menu noext-menu-hidden"><li><a class="first-link" href="PMC3343166.html#"> Other Sections▼</a><ul class="submenu head1"><li class="submenu-item"><a href="PMC3343166.html#__abstractid270123" class="" style="text-transform: none;">Abstract</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270156" class="" style="text-transform: none;">INTRODUCTION</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270197" class="" style="text-transform: none;">MATERIALS AND METHODS</a></li><li class="submenu-item current-item"><a class="" href="PMC3343166.html#" onclick="return(false)" style="text-transform: none;">RESULTS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270297" class="" style="text-transform: none;">DISCUSSION</a></li><li class="submenu-item"><a href="PMC3343166.html#__ref-listid270428" class="" style="text-transform: none;">References</a></li></ul></li></ul></div><div>RESULTS</div></div><div class="section-content" id="__secid270248content"><div class="p p-first" id="__pid270252">Of the 1,679 total patients who were enrolled for the study, 199 were excluded from the final analysis for the following reasons: age &#x0003c;19 years (5 patients), previous sphincterotomy (90 patients), acute pancreatitis before ERCP (97 patients), pregnancy (3 patients), and absence of post-ERCP evaluation (4 patients). The "previous sphincterotomy" group included any patients with a history of a biliary sphincterotomy, biliary stent removal or replacement, or confirmation of biliary clearance after stone extraction.</div><div class="p" id="__pid270254">Ultimately, data from 1,480 patients (gabexate mesylate group, 593; ulinastatin group, 229; control group, 658) were analyzed. The mean age was 65.19&#x000b1;15.23 years, and 691 (46.7%) patients were women. The most common indication for ERCP was choledocholithiasis (59.1%, 874/1,480), followed by cholecystolithiasis (10.9%, 162/1,480), cholangiocarcinoma (9.9%, 146/1,480), and pancreatic cancer (5.2%, 77/1,480). The gabexate mesylate, ulinastatin, and control groups were similar in respect to patient demographics and the common distribution of indications for the procedure (<a href="http://europepmc.org/articles/PMC3343166/table/T1/" style="text-decoration:none;" onclick="return startTarget(this, 'true', 1024, 800)" class="fig-table-link table figpopup" rid-figpopup="T1"><span style="text-decoration: underline;">Table 1</span></a>). Patients were classified as high risk if they had any of the high-risk parameters identified by Freeman and Guda,<sup><a href="http://europepmc.org/abstract/MED/15173799" rid="B9" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">9</a></sup> such as young age, suspected sphincter of Oddi dysfunction, prior pancreatitis, difficult cannulation, or precut sphincterotomy. Of the total 252 high-risk patients, 102 were in the gabexate mesylate group, 44 were in the ulinastatin group, and 106 were in the control group. The incidence of high-risk factors for PEP was similar in the 3 groups (<a href="http://europepmc.org/articles/PMC3343166/table/T1/" style="text-decoration:none;" onclick="return startTarget(this, 'true', 1024, 800)" class="fig-table-link table figpopup" rid-figpopup="T1"><span style="text-decoration: underline;">Table 1</span></a>).</div><div class="canvas-table-ref-outer"><div class="canvas-table-ref-inner"><table class="thumb-caption" border="0" cellpadding="0" cellspacing="0" style="clear:both; width: 100%;"><tr valign="top" align="left"><td class="thumb-cell"><div class="thumb-ph" id="T1"><a href="http://europepmc.org/articles/PMC3343166/table/T1/" onclick="return startTarget(this, 'table', 1024, 800)" class="table"><img src="../corehtml/pmc/pmcgifs/table-icon.gif" class="icon-reflink" border="0" alt="Table 1" title="Table 1" /></a></div></td><td class="caption-cell"><div class="caption-ph"><a class="side-caption" href="http://europepmc.org/articles/PMC3343166/table/T1/" onclick="return startTarget(this, 'figure', 1024, 800)"><strong>Table 1</strong></a><div class="figure-table-caption-in-article"><span>Baseline Characteristics of Patients in the Gabexate Mesylate, Ulinastatin, and Control Groups</span></div><div class="figure-table-caption-in-article"></div></div></td></tr></table></div></div><div class="p" id="__pid270273">Endoscopic sphincterotomy was performed in about 63.8% (944/1,480) of the therapeutic endoscopic procedures, with no significant differences among the 3 groups. Also similar were the rates of patients with bile duct cannulation failure, precut sphincterotomy, endoscopic sphincterotomy and/or stone extraction, endoscopic papillary balloon dilation (EPBD) and/or stone extraction, stricture dilation, endoscopic retrograde biliary drainage, and endoscopic papillectomy (<a href="http://europepmc.org/articles/PMC3343166/table/T2/" style="text-decoration:none;" onclick="return startTarget(this, 'true', 1024, 800)" class="fig-table-link table figpopup" rid-figpopup="T2"><span style="text-decoration: underline;">Table 2</span></a>). However, EPBD was performed more in the ulinastatin group (19.7%, 45/229) than in the gabexate mesylate group (10.8%, 64/593) and control group (10.7%, 70/658), and this difference was significant (p=0.001).</div><div class="canvas-table-ref-outer"><div class="canvas-table-ref-inner"><table class="thumb-caption" border="0" cellpadding="0" cellspacing="0" style="clear:both; width: 100%;"><tr valign="top" align="left"><td class="thumb-cell"><div class="thumb-ph" id="T2"><a href="http://europepmc.org/articles/PMC3343166/table/T2/" onclick="return startTarget(this, 'table', 1024, 800)" class="table"><img src="../corehtml/pmc/pmcgifs/table-icon.gif" class="icon-reflink" border="0" alt="Table 2" title="Table 2" /></a></div></td><td class="caption-cell"><div class="caption-ph"><a class="side-caption" href="http://europepmc.org/articles/PMC3343166/table/T2/" onclick="return startTarget(this, 'figure', 1024, 800)"><strong>Table 2</strong></a><div class="figure-table-caption-in-article"><span>Therapeutic Procedures for Each Group</span></div><div class="figure-table-caption-in-article"></div></div></td></tr></table></div></div><div id="__secid270281" class="sec"><div class="head2 head-separate">1. Post-ERCP hyperamylasemia and PEP</div><div class="p p-first-last" id="__pid270284">The overall incidence of post-ERCP hyperamylasemia was 12.9% (192/1,480). There was no significant difference in the rate of post-ERCP hyperamylasemia between the gabexate mesylate (12.3%, 73/593), ulinastatin (10.9%, 25/229), and control (14.3%, 94/658) groups (p=0.351). PEP was developed in 5.7% (85/1,480) of the patients. There was a significant difference in the rate of PEP between the gabexate mesylate (3.5%, 21/593), ulinastatin (7.0%, 16/229), and control (7.3%, 48/658) groups (p=0.012). Moreover, patients who were given gabexate mesylate (3.5%) had lower rates of PEP than those who were given ulinastatin (7.0%), and this difference was statistically significant (p=0.039). Among the 85 patients who developed pancreatitis, 24 (28.3%) had moderate to severe pancreatitis (3 patients in the gabexate mesylate group, 6 in the ulinastatin group, and 15 in the control group). There was a significant difference in the rate of moderate to severe PEP between the gabexate mesylate (0.5%, 3/593), ulinastatin (2.6%, 6/229), and control(2.3%, 15/658) groups (p=0.020) (<a href="http://europepmc.org/articles/PMC3343166/table/T3/" style="text-decoration:none;" onclick="return startTarget(this, 'true', 1024, 800)" class="fig-table-link table figpopup" rid-figpopup="T3"><span style="text-decoration: underline;">Table 3</span></a>).</div><div class="canvas-table-ref-outer"><div class="canvas-table-ref-inner"><table class="thumb-caption" border="0" cellpadding="0" cellspacing="0" style="clear:both; width: 100%;"><tr valign="top" align="left"><td class="thumb-cell"><div class="thumb-ph" id="T3"><a href="http://europepmc.org/articles/PMC3343166/table/T3/" onclick="return startTarget(this, 'table', 1024, 800)" class="table"><img src="../corehtml/pmc/pmcgifs/table-icon.gif" class="icon-reflink" border="0" alt="Table 3" title="Table 3" /></a></div></td><td class="caption-cell"><div class="caption-ph"><a class="side-caption" href="http://europepmc.org/articles/PMC3343166/table/T3/" onclick="return startTarget(this, 'figure', 1024, 800)"><strong>Table 3</strong></a><div class="figure-table-caption-in-article"><span>Incidence of Post-ERCP Hyperamylasemia and Post-ERCP Pancreatitis in Each Group</span></div><div class="figure-table-caption-in-article"></div></div></td></tr></table></div></div></div><div id="__secid270291" class="sec sec-last"><div class="head2 head-separate">2. Side effects</div><div class="p p-first-last" id="__pid270294">None of the patients experienced any adverse effects related to gabexate mesylate, ulinastatin or saline solution administration, such as shock, itching, rash, nausea, vomiting, or neutropenia.</div></div></div></div><div id="__secid270297" class="sec"><div class="head1 section-title" id="__secid270297titletitle" style="text-transform: none;"><div class="other-sections"><ul class="noext-menu noext-menu-hidden"><li><a class="first-link" href="PMC3343166.html#"> Other Sections▼</a><ul class="submenu head1"><li class="submenu-item"><a href="PMC3343166.html#__abstractid270123" class="" style="text-transform: none;">Abstract</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270156" class="" style="text-transform: none;">INTRODUCTION</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270197" class="" style="text-transform: none;">MATERIALS AND METHODS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270248" class="" style="text-transform: none;">RESULTS</a></li><li class="submenu-item current-item"><a class="" href="PMC3343166.html#" onclick="return(false)" style="text-transform: none;">DISCUSSION</a></li><li class="submenu-item"><a href="PMC3343166.html#__ref-listid270428" class="" style="text-transform: none;">References</a></li></ul></li></ul></div><div>DISCUSSION</div></div><div class="section-content" id="__secid270297content"><div class="p p-first" id="__pid270301">ERCP and sphincterotomy are essential procedures for managing pancreaticobiliary disease. Among the complications of ERCP, acute pancreatitis is the most frequent and troublesome. The pathogenesis of PEP is not well understood but is most likely multifactorial. Hypothesized mechanisms of pancreatic injury include mechanical, chemical, hydrostatic, thermal, enzymatic, microbiologic, allergic, immunologic reactions, etc. On the basis of the hypothesis, various attempts have been made to prevent PEP, such as change of technique, patient selection, pancreatic stenting, and pharmacologic prophylaxis.<sup><a href="http://europepmc.org/abstract/MED/12555013" rid="B10" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">10</a></sup></div><div class="p" id="__pid270307">Many pharmacologic agents of different types have been used to prevent PEP on the assumption that they may pharmacologically inhibit one or more of the aforementioned factors associated with pancreatic damage. Irrespective of the etiology of acute pancreatitis, the activation of proteolytic enzymes, starting with trypsinogen activation to trypsin in pancreatic acinar cells, has been considered to play an initial role in the pathogenesis of pancreatitis. Trypsin would subsequently trigger the activation of other enzymes and the inflammatory cascade. Antiproteases, which have been used to manage acute pancreatitis in routine clinical settings in some countries,<sup><a href="http://europepmc.org/abstract/MED/17625308" rid="B11" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">11</a></sup> may be theoretically useful for preventing PEP. Prevention of PEP with antiproteases, gabexate, or ulinastatin, has been evaluated in several studies. Some studies clearly demonstrated that gabexate mesylate or ulinastatin is effective in reducing the incidence of PEP,<sup><a href="http://europepmc.org/abstract/MED/8786777" rid="B2" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">2</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/15822043" rid="B4" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">4</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/17531632" rid="B8" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">8</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/12297762" rid="B12" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">12</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/17351806" rid="B13" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">13</a></sup> other studies did not find any benefit in administrating either drug.<sup><a href="http://europepmc.org/abstract/MED/15290665" rid="B3" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">3</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/18953247" rid="B5" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">5</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/12297762" rid="B12" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">12</a></sup> Compared with gabexate mesylate, ulinastatin has a stronger inhibitory effect on pancreatic enzymes in various experimental models of pancreatitis.<sup><a href="http://europepmc.org/abstract/MED/6345304" rid="B14" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">14</a></sup> To date, however, very a few reports comparing the efficacy of gabexate mesylate and ulinastatin with regard to the prevention of PEP have been published. Two Japanese clinical trials compared gabexate mesylate with ulinastatin administered before and after ERCP, and the rates of PEP were not significantly different.<sup><a href="http://europepmc.org/abstract/MED/17351806" rid="B13" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">13</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/16724996" rid="B15" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">15</a></sup></div><div class="p" id="__pid270372">In our study, in a consecutive series of hospitalized patients who underwent ERCP, we compared the effects of a 24-hour continuous intravenous drip infusion of either 400 mg of gabexate mesylate or 150,000 units of ulinastatin, beginning 30 minutes before the ERCP. We found that gabexate mesylate prophylaxis before and after ERCP was effective in preventing PEP. However, prophylactic administration of ulinastatin did not show a beneficial efficacy to prevent PEP. Recent systemic review reported ulinastatin shows to be of value on preventing PEP and hyperamylasemia for patients in average risk, when given intravenously at a dose of not less than 150,000 unit, just before ERCP.<sup><a href="http://europepmc.org/abstract/MED/20531245" rid="B16" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">16</a></sup> In our study, we designed to 150,000 unit of ulinastatin infusion duration for 24 hours start from 30 minutes before ERCP. Considering duration of infusion and difference of infusion dose intensity, it could make different result from other previous studies.</div><div class="p" id="__pid270380">In general, because of its short half-life, gabexate should be administered continuously for a long period of time (greater than 12 hours) and at a relatively high dose (greater than 500 mg to 1 g) in order to prevent pancreatitis.<sup><a href="http://europepmc.org/abstract/MED/8786777" rid="B2" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">2</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/17531632" rid="B8" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">8</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/14572565" rid="B17" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">17</a></sup> In the present study, we used a relatively low dose of gabexate mesylate (400 mg) compared with the previous studies (500 mg or 1 g). In Korea, the cost of 400 mg of gabexate mesylate is about US $18, whereas 150,000 units of ulinastatin is US $44. And the cost of continuous infusion of 0.75 mg and 3 mg of somatostatin, another widely evaluated and possibly effective drug, is about US $40 and US $109, respectively. Thus, gabexate mesylate is more cost effective than either alternative drug. The important results of the present study show that a 24-hour infusion of 400 mg of gabexate mesylate at a relatively lower dose than in previous studies significantly reduced the incidence of PEP.</div><div class="p" id="__pid270398">The increasing risk of pancreatitis after EPBD remains a controversial but serious issue. In an American study,<sup><a href="http://europepmc.org/abstract/MED/15520997" rid="B18" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">18</a></sup> the incidence of pancreatitis was unacceptably high in an EPBD group (15.4%, 18/117), and 2 of 6 patients with severe pancreatitis died. This unfortunate result is in striking contrast to the results of an uncontrolled study and a randomized controlled study; no fatal pancreatitis was observed after EPBD in a total of more than 600 patients reported.<sup><a href="http://europepmc.org/abstract/MED/10202061" rid="B19" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">19</a></sup><sup>,</sup><sup><a href="http://europepmc.org/abstract/MED/12665764" rid="B20" class="cite-reflink bibr popnode" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CBody&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">20</a></sup> In our current study, although EPBD is not associated with a risk for PEP (odds ratio, 0.69; 95% confidence interval, 0.09 to 5.36; p=0.722) on univariated analysis, EPBD was performed significantly more in the ulinastatin group (19.7%, 45/229) than in the gabexate mesylate group (10.8%, 64/593) and control group (10.7%, 70/658). This difference may have an effect on the incidence of PEP.</div><div class="p" id="__pid270417">The current study has some limitations. The 3 groups were not randomized, the number of patients with ulinastatin prophylaxis was relatively small compared with other groups, and the analysis was retrospective. In our center, we had changed strategy to premedication for prophylaxis of PEP. It was gabexate mesylate in January 2005 to December 2006, no prophylactic medication in January 2007 to August 2009, and ulinastatin in September 2009 to April 2010. So variation on number of groups is a reflection of changes on number of patients at our center. The study was done in a single large tertiary care center. Most patients needed therapeutic intervention, including endoscopic sphincterotomy or EPBD, and were admitted via the emergency department because of acute cholangitis or severe abdominal pain. Thus, we performed ERCP on an inpatient basis, and continuous intravenous infusion of gabexate mesylate or ulinastatin could be started before the procedure and continued 24 hours thereafter. Thus, it may be impractical to use gabexate mesylate or ulinastatin during outpatient procedures in elective cases.</div><div class="p p-last" id="__pid270419">In conclusion, 24-hour infusion of 400 mg of gabexate mesylate at a relatively low dose significantly reduced the incidence of PEP. However, prophylactic administration of ulinastatin, compared with gabexate mesylate and control group, did not show a beneficial influence on the incidence of PEP. Further prospective randomized large multicenter studies are needed.</div></div></div><div id="__fn-groupid270422" class="sec"><div class="head1 section-title" id="__fn-groupid270422titletitle" style="text-transform: none;"><div>Footnotes</div></div><div class="section-content" id="__fn-groupid270422content"><div class="fn-group fm-footnote"><div class="fn p" id="__fnid270424"> No potential conflict of interest relevant to this article was reported.</div></div></div></div><div id="__ref-listid270428" class="sec"><div class="head1 section-title" id="__ref-listid270428titletitle" style="text-transform: none;"><div class="other-sections"><ul class="noext-menu noext-menu-hidden"><li><a class="first-link" href="PMC3343166.html#"> Other Sections▼</a><ul class="submenu head1"><li class="submenu-item"><a href="PMC3343166.html#__abstractid270123" class="" style="text-transform: none;">Abstract</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270156" class="" style="text-transform: none;">INTRODUCTION</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270197" class="" style="text-transform: none;">MATERIALS AND METHODS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270248" class="" style="text-transform: none;">RESULTS</a></li><li class="submenu-item"><a href="PMC3343166.html#__secid270297" class="" style="text-transform: none;">DISCUSSION</a></li><li class="submenu-item current-item"><a class="" href="PMC3343166.html#" onclick="return(false)" style="text-transform: none;">References</a></li></ul></li></ul></div><div>References</div></div><div class="section-content" id="__ref-listid270428content"><div class="sec"><div class="back-matter-section" id="reference-list"><div class="ref-cit-blk" id="B1"><span class="ref-label">1.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270433">Dumonceau JM, Andriulli A, Deviere J, et al.  European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. <span><span class="ref-journal">Endoscopy. </span>2010;<span class="ref-vol">42</span>:503–515.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/20506068" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B2"><span class="ref-label">2.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270475">Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy: Italian Group. <span><span class="ref-journal">N Engl J Med. </span>1996;<span class="ref-vol">335</span>:919–923.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/8786777" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B3"><span class="ref-label">3.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270531">Andriulli A, Solmi L, Loperfido S, et al.  Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2004;<span class="ref-vol">2</span>:713–718.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/15290665" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B4"><span class="ref-label">4.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270574">Tsujino T, Komatsu Y, Isayama H, et al.  Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2005;<span class="ref-vol">3</span>:376–383.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/15822043" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B5"><span class="ref-label">5.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270617">Yoo JW, Ryu JK, Lee SH, et al.  Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. <span><span class="ref-journal">Pancreas. </span>2008;<span class="ref-vol">37</span>:366–370.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/18953247" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B6"><span class="ref-label">6.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270658">Choi CW, Kang DH, Kim GH, et al.  Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. <span><span class="ref-journal">Gastrointest Endosc. </span>2009;<span class="ref-vol">69</span>:e11–e18.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/19327467" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B7"><span class="ref-label">7.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270701">Cotton PB, Lehman G, Vennes J, et al.  Endoscopic sphincterotomy complications and their management: an attempt at consensus. <span><span class="ref-journal">Gastrointest Endosc. </span>1991;<span class="ref-vol">37</span>:383–393.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/2070995" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B8"><span class="ref-label">8.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270742">Manes G, Ardizzone S, Lombardi G, Uomo G, Pieramico O, Porro GB. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. <span><span class="ref-journal">Gastrointest Endosc. </span>2007;<span class="ref-vol">65</span>:982–987.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/17531632" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B9"><span class="ref-label">9.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270799">Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. <span><span class="ref-journal">Gastrointest Endosc. </span>2004;<span class="ref-vol">59</span>:845–864.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/15173799" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B10"><span class="ref-label">10.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270834">Testoni PA. Preventing post-ERCP pancreatitis: where are we? <span><span class="ref-journal">JOP. </span>2003;<span class="ref-vol">4</span>:22–32.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/12555013" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B11"><span class="ref-label">11.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270864">Tsujino T, Kawabe T, Omata M. Antiproteases in preventing post-ERCP acute pancreatitis. <span><span class="ref-journal">JOP. </span>2007;<span class="ref-vol">8</span>(4 Suppl):509–517.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/17625308" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B12"><span class="ref-label">12.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270907">Andriulli A, Clemente R, Solmi L, et al.  Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. <span><span class="ref-journal">Gastrointest Endosc. </span>2002;<span class="ref-vol">56</span>:488–495.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/12297762" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B13"><span class="ref-label">13.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270948">Ueki T, Otani K, Kawamoto K, et al.  Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. <span><span class="ref-journal">J Gastroenterol. </span>2007;<span class="ref-vol">42</span>:161–167.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/17351806" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B14"><span class="ref-label">14.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid270990">Ohnishi H, Kosuzume H, Ashida Y, Kato K, Suzuki Y, Honjo I. Therapeutic effects of human urinary trypsin inhibitor on acute experimental pancreatitis. <span><span class="ref-journal">Nihon Yakurigaku Zasshi. </span>1983;<span class="ref-vol">81</span>:235–244.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/6345304" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B15"><span class="ref-label">15.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid271046">Fujishiro H, Adachi K, Imaoka T, et al.  Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. <span><span class="ref-journal">J Gastroenterol Hepatol. </span>2006;<span class="ref-vol">21</span>:1065–1069.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/16724996" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B16"><span class="ref-label">16.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid271601">Chen S, Shi H, Zou X, Luo H. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp? <span><span class="ref-journal">Pancreas. </span>2010;<span class="ref-vol">39</span>:1231–1237.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/20531245" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B17"><span class="ref-label">17.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid271647">Masci E, Cavallini G, Mariani A, et al.  Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. <span><span class="ref-journal">Am J Gastroenterol. </span>2003;<span class="ref-vol">98</span>:2182–2186.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/14572565" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B18"><span class="ref-label">18.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid271689">Disario JA, Freeman ML, Bjorkman DJ, et al.  Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. <span><span class="ref-journal">Gastroenterology. </span>2004;<span class="ref-vol">127</span>:1291–1299.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/15520997" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B19"><span class="ref-label">19.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid271730">Ueno N, Ozawa Y. Pancreatitis induced by endoscopic balloon sphincter dilation and changes in serum amylase levels after the procedure. <span><span class="ref-journal">Gastrointest Endosc. </span>1999;<span class="ref-vol">49</span>(4 Pt 1):472–476.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/10202061" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div><div class="ref-cit-blk" id="B20"><span class="ref-label">20.</span> <span class="ref-cit"><span class="element-citation" id="__element-citationid271769">Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y. Predictive factors for acute pancreatitis and hyperamylasemia after endoscopic papillary balloon dilation. <span><span class="ref-journal">Gastrointest Endosc. </span>2003;<span class="ref-vol">57</span>:531–535.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="http://europepmc.org/abstract/MED/12665764" target="pmc_ext" onclick="focuswin('pmc_ext')" ref="reftype=pubmed&amp;article-id=2353728&amp;issue-id=97218&amp;journal-id=734&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></span></div></div></div></div></div>

<script type="text/javascript">
$(document).ready(function(){
   $('A.cite-reflink[rid]').mouseover(function(){ TagToTip($(this).attr('rid'), WIDTH, 300, FIX, [this, 0, 0], ABOVE, true); });
   $('A.cite-reflink[rid]').mouseout(function() { UnTip(); });
});
</script>


<div align="center">
Articles from <span class="acknowledgment-journal-title">Gut and Liver</span> are provided here courtesy of <br /><b>The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, the Korean Society of Pancreatobiliary Disease, and the Korean Society of Gastrointestinal Cancer</b>
</div>
</td>
</tr>
</table>
</div>
<div class="ui-tabs-panel ui-tabs-hide" id="fragment-related-citations">
<div id="id25"><div><img src="../resources/org.apache.wicket.ajax.AbstractDefaultAjaxBehavior/indicator.gif"/></div></div>
</div>
<div class="ui-tabs-panel ui-tabs-hide" id="fragment-related-bioentities">
<div id="id26"><div><img src="../resources/org.apache.wicket.ajax.AbstractDefaultAjaxBehavior/indicator.gif"/></div></div>
</div>
<div class="ui-tabs-panel ui-tabs-hide" id="fragment-related-pubmedarts">
<div width="100%" id="id27"><div><img src="../resources/org.apache.wicket.ajax.AbstractDefaultAjaxBehavior/indicator.gif"/></div></div>
</div>
</div>
</div>
<div class="page_info_margin">

<div>
<div>
<script type="text/javascript">$(document).ready(function(){
 document.getElementById("fulltextnavpanel").className='citation_navigation_selected';
 });</script>



<div id="vertmenu">
<h5>Formats</h5>
<ul>
<li>
<div class="citation_navigation_unselected">
<a href="http://europepmc.org/abstract/MED/22570757" tabindex="1">Abstract</a>
</div>
</li>
<li>
<div id="fulltextnavpanel" class="citation_navigation_unselected">
Full Text <img border="0" src="../images/small_logo.gif" height="14" width="14"/>
</div>
</li>

<li>
<div class="citation_navigation_unselected" >
<a target="_blank" href="http://europepmc.org/articles/PMC3343166/pdf/gnl-6-256.pdf" tabindex="4">PDF (279K)</a>
</div>
</li>
<li>
<div class="citation_navigation_unselected" >
<div style="border-top: 1px dashed #cccccc;">
<a style="display:inline-block;" href="http://europepmc.org/?wicket:interface=:4:fulltextmarginpanel:export:exportlink::ILinkListener::">
<small>
<span><b>Export</b> citation (RIS)</span>
</small>
</a>
<a style="display:inline-block; background-color:#fff;" href="http://europepmc.org/FAQ#RIS_Format" target="_top"><img border="0" src="../images/qmark.png" alt="Export Citation in Research Information Systems (RIS) Format" onmouseover="Tip('The Research Information Systems (RIS) Format is compatible with&lt;br/&gt;EndNote, Mendeley, Reference Manager, ProCite and RefWorks.')" onmouseout="UnTip()"/></a>
</div>
</div>
<div class="citation_navigation_unselected" >
<div>
<a style="display:inline-block;" href="http://europepmc.org/?wicket:interface=:4:fulltextmarginpanel:email:emaillink::ILinkListener::" onclick="var w = window.open(href, 'europe_pmc_email_clipboard', 'scrollbars=no,location=no,menuBar=no,resizable=no,status=no,toolbar=no,width=550,height=600'); if(w.blur) w.focus(); return false;" target="europe_pmc_email_clipboard">
<small>
<span><b>Email</b> citation</span>
</small>
</a>
</div>
</div>
</li>
</ul>

<br/>
<h5>Journal and Issue</h5>
<div id="vertsubmenu" class="journalIssue">
<ul>
<li>
<a href="http://europepmc.org/journals/">Journal List</a><a href="http://europepmc.org/journals/734/">Gut Liver</a><a href="http://europepmc.org/issues/97218/">v.6(2); Apr 2012</a>
</li>
</ul>
</div>

</div>
<br/>
</div>
</div>


<div>
<div id="vertmenu" style="overflow: auto;">
<h5>BioEntities in Full Text</h5>
<div id="vertsubmenu">
<div class="mesh_category"><span>Genes/Proteins</span></div>
<div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_gene_protein=http://www.uniprot.org/uniprot/?query=name:&quot;lipase&quot;" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">lipase (2)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22lipase%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div><div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_gene_protein=http://www.uniprot.org/uniprot/?query=name:&quot;trypsin&#32;inhibitor&quot;" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">trypsin inhibitor (1)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22trypsin+inhibitor%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div><div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_gene_protein=http://www.uniprot.org/uniprot/?query=name:&quot;trypsin&quot;" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">trypsin (1)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22trypsin%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div>
<div class="more">
<small><span><a href="PMC3343166.html#" id="gene_protein" style="color: #666666;"><b>1 more...</b></a></span></small>
</div>
<span><script type="text/javascript">
var $tabs = $('#container-1 > ul').tabs();
 $('#gene_protein').click(function() {
$tabs.tabs('select', 2); 
 return true;
});
 </script>
</span>
</div>
<div id="vertsubmenu">
<div class="mesh_category"><span>Gene Ontology (GO)</span></div>
<div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_go_term=http://www.uniprot.org/uniprot/?query=go:0009405&amp;sort=score" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">pathogenesis (3)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22pathogenesis%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div><div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_go_term=http://www.uniprot.org/uniprot/?query=go:0007565&amp;sort=score" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">pregnancy (2)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22pregnancy%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div>
<div class="more">
<small></small>
</div>
<span><script type="text/javascript">
var $tabs = $('#container-1 > ul').tabs();
 $('#go_term').click(function() {
$tabs.tabs('select', 2); 
 return true;
});
 </script>
</span>
</div>
<div id="vertsubmenu">
<div class="mesh_category"><span>Species</span></div>
<div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_Species=http://www.uniprot.org/uniprot/?query=organism:9606&amp;sort=score" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">human (1)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22human%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div>
<div class="more">
<small></small>
</div>
<span><script type="text/javascript">
var $tabs = $('#container-1 > ul').tabs();
 $('#Species').click(function() {
$tabs.tabs('select', 2); 
 return true;
});
 </script>
</span>
</div>
<div id="vertsubmenu">
<div class="mesh_category"><span>Diseases</span></div>
<div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_Diseases=/search/?page=1&amp;query=Pancreatitis">
<span class="bioent_name">Pancreatitis (31)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22Pancreatitis%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div><div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_Diseases=/search/?page=1&amp;query=hyperamylasemia">
<span class="bioent_name">hyperamylasemia (9)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22hyperamylasemia%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div><div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_Diseases=/search/?page=1&amp;query=Acute&#32;pancreatitis">
<span class="bioent_name">Acute pancreatitis (9)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22Acute+pancreatitis%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div>
<div class="more">
<small><span><a href="PMC3343166.html#" id="Diseases" style="color: #666666;"><b>13 more...</b></a></span></small>
</div>
<span><script type="text/javascript">
var $tabs = $('#container-1 > ul').tabs();
 $('#Diseases').click(function() {
$tabs.tabs('select', 2); 
 return true;
});
 </script>
</span>
</div>
<div id="vertsubmenu">
<div class="mesh_category"><span>Chemicals</span></div>
<div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_Chemicals=http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:35480" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">analgesics (3)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22analgesics%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div><div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_Chemicals=http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28787" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">nitroglycerin (2)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22nitroglycerin%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div><div>
<div class="bioent_item">
<a href="http://europepmc.org/articles/PMC3343166?europe_pmc_bio_tm_extredirect_Chemicals=http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:35481" onclick="var w = window.open(href, '', 'scrollbars=yes,location=no,menuBar=no,resizable=yes,status=no,toolbar=no,width=900,height=900'); if(w.blur) w.focus(); return false;">
<span class="bioent_name">non-narcotic analgesics (1)</span>
</a>
</div>
<div class="search">
<a href="http://europepmc.org/search/?page=1&amp;query=%22non-narcotic+analgesics%22">

<img src="../resources/uk.bl.ukpmc.web.panels.images.SearchIcon/search_magnifier.gif" border="0" height="14" width="14" align="top" onmouseover="Tip('Perform a new search')" onmouseout="UnTip()"/>

</a>
</div>
</div>
<div class="more">
<small><span><a href="PMC3343166.html#" id="Chemicals" style="color: #666666;"><b>12 more...</b></a></span></small>
</div>
<span><script type="text/javascript">
var $tabs = $('#container-1 > ul').tabs();
 $('#Chemicals').click(function() {
$tabs.tabs('select', 2); 
 return true;
});
 </script>
</span>
</div>
</div>
</div>

</div>

<span>
<script type="text/javascript">
function getXMLHttpRequestObject()
{
var xmlhttp;
if (!xmlhttp && typeof XMLHttpRequest != 'undefined') {
try {
xmlhttp = new XMLHttpRequest();
} catch (e) {
xmlhttp = false;
}
}
return xmlhttp;
}
function getArticleXMLHttpRequestToUrl(url)
{
var http = new getXMLHttpRequestObject();
var abs = "/articles/"
http.open("GET", abs+url, true);
http.onreadystatechange = function() {
}
http.send(null);
}
function getAbstractXMLHttpRequestToUrl(url)
{
var http = new getXMLHttpRequestObject();
var abs = "/abstract/"
http.open("GET", abs+url, true);
http.onreadystatechange = function() {
}
http.send(null);
}
function getXMLHttpRequestForVisualisation(url)
{
var http = new getXMLHttpRequestObject();
http.open("GET",url, true);
http.onreadystatechange = function() {
}
http.send(null);
}
</script>
</span>
</div>
<!--<script type="text/javascript">
function getXMLHttpRequestObject()
{
var xmlhttp;
if (!xmlhttp && typeof XMLHttpRequest != 'undefined') {
try {
xmlhttp = new XMLHttpRequest();
} catch (e) {
xmlhttp = false;
}
}
return xmlhttp;
}
function getArticleXMLHttpRequestToUrl(url)
{
var http = new getXMLHttpRequestObject();
var abs = "/articles/"
http.open("GET", abs+url, true);
http.onreadystatechange = function() {
//Handler function for call back on state change.
if(http.readyState == 4) {
}
}
http.send(null);
}
function getXMLHttpRequestForVisualisation(url)
{
var http = new getXMLHttpRequestObject();
http.open("GET",url, true);
http.onreadystatechange = function() {
//Handler function for call back on state change.
if(http.readyState == 4) {
}
}
http.send(null);
}
</script>
-->

</div>
<div id="epmc_pageFooter">
<div>
<p class="epmc_footerNav">
<a href="http://www.ebi.ac.uk/Information/termsofuse.html" target="_blank" class="results2">Terms of Use</a>
&#160;&#160;|&#160;&#160;
<a href="http://europepmc.org/Copyright" target="_top" class="results2">Copyright</a>
&#160;&#160;|&#160;&#160;
<a href="http://europepmc.org/Accessibility" target="_top" class="results2">Accessibility</a>
&#160;&#160;|&#160;&#160;
<a href="http://www.ebi.ac.uk/Information/e-directive.html#cookies" target="_blank" class="results2">Cookies</a>
</p>
<div class="epmc_footerText">Europe PubMed Central is a service of the <a href="http://europepmc.org/Funders/" target="_top" class="link">Europe PMC
Funders' Group</a> working in partnership with the <a href="http://www.ebi.ac.uk" target="_blank" class="link">European
Bioinformatics Institute</a>, <a
href="http://www.manchester.ac.uk" target="_blank" class="link">University of
Manchester</a> and the <a
href="http://www.bl.uk/science" target="_blank" class="link">British Library</a> in cooperation with the <a
href="http://www.ncbi.nlm.nih.gov/" target="_blank" class="link">National Center
for Biotechnology Information</a> at the <a href="http://www.nlm.nih.gov"
target="_blank" class="link">U.S. National Library of Medicine (NCBI/NLM)</a>. It
includes content provided to the <a
href="http://www.pubmedcentral.nih.gov" target="_blank" class="link">PubMed
Central International archive</a> by participating publishers.
</div>
<script src="../template/jquery.cookie.js" type="text/javascript"></script>
<script src="../Scripts/jquery.gchart.min.js" type="text/javascript"></script>
<script src="../Scripts/css_browser_selector.js" type="text/javascript"></script>
</div>
</div>
</div>
<script type="text/javascript" src="../Scripts/wz_tooltip.js"></script>
<script type="text/javascript" src="../Scripts/jquery.corner.js"></script>
<script type="text/javascript">
$(document).ready(function(){
$('#container-1 > ul').tabs();
});
</script>
</body>
</html>
